The Neuroprotective Action of Resveratrol Against Cognitive Impairments Induced by Lorazepam in Male Rats.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2024-10-09 DOI:10.2174/0115748863312358240919103439

Anup Kumar Chakraborty, Prashant Tiwari, Deepak Shamrao Khobragade, Sunil Kumar Kadiri, Imran A Sheikh, Jyoti Thakur

{"title":"The Neuroprotective Action of Resveratrol Against Cognitive Impairments Induced by Lorazepam in Male Rats.","authors":"Anup Kumar Chakraborty, Prashant Tiwari, Deepak Shamrao Khobragade, Sunil Kumar Kadiri, Imran A Sheikh, Jyoti Thakur","doi":"10.2174/0115748863312358240919103439","DOIUrl":null,"url":null,"abstract":"Introduction/aim: The study examines how chronic resveratrol administration affects behavioral and neurochemical changes caused by Lorazepam (LZP), a classical anti-anxiety medicine associated with neurodegenerative and neurological problems.Method: Forty male rats were placed into four groups: a control group receiving 1% Tween 80, the LZP group receiving 2 mg/kg/day, the Resveratrol group receiving 50 mg/kg/day, and the LZP plus resveratrol group receiving the same doses of LZP and Resveratrol. Oral therapy was given daily for 6 weeks. The animals were euthanized after open field and Y maze behavioral tests. In specific brain regions, neurochemical analyses were performed on GABA, glutamic acid, monoamines (norepinephrine, dopamine, and serotonin) and their metabolites, DNA fragmentation (8-hydroxy-2-deoxyguanosine or 8-HdG), brain-derived neurotrophic factor (BDNF), and Ca-ATPase.Results: Resveratrol therapy improved GABA, glutamic acid, monoamines, and their metabolites in the cerebral cortex, hippocampus, and striatum. Additionally, it reduced DNA fragmentation (8- HdG) and counteracted LZP-induced Ca-ATPase downregulation at a significant level (p < 0.05). Resveratrol also reversed LZP-induced behavioral changes in the Y maze and open field tests.Conclusion: Resveratrol has anxiolytic-like actions like benzodiazepines and neuroprotective capabilities against LZP-induced adverse effects.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115748863312358240919103439","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction/aim: The study examines how chronic resveratrol administration affects behavioral and neurochemical changes caused by Lorazepam (LZP), a classical anti-anxiety medicine associated with neurodegenerative and neurological problems.

Method: Forty male rats were placed into four groups: a control group receiving 1% Tween 80, the LZP group receiving 2 mg/kg/day, the Resveratrol group receiving 50 mg/kg/day, and the LZP plus resveratrol group receiving the same doses of LZP and Resveratrol. Oral therapy was given daily for 6 weeks. The animals were euthanized after open field and Y maze behavioral tests. In specific brain regions, neurochemical analyses were performed on GABA, glutamic acid, monoamines (norepinephrine, dopamine, and serotonin) and their metabolites, DNA fragmentation (8-hydroxy-2-deoxyguanosine or 8-HdG), brain-derived neurotrophic factor (BDNF), and Ca-ATPase.

Results: Resveratrol therapy improved GABA, glutamic acid, monoamines, and their metabolites in the cerebral cortex, hippocampus, and striatum. Additionally, it reduced DNA fragmentation (8- HdG) and counteracted LZP-induced Ca-ATPase downregulation at a significant level (p < 0.05). Resveratrol also reversed LZP-induced behavioral changes in the Y maze and open field tests.

Conclusion: Resveratrol has anxiolytic-like actions like benzodiazepines and neuroprotective capabilities against LZP-induced adverse effects.

查看原文本刊更多论文

白藜芦醇对洛拉西泮引起的雄性大鼠认知障碍的神经保护作用

引言/目的：本研究探讨了长期服用白藜芦醇如何影响劳拉西泮（LZP）引起的行为和神经化学变化：将 40 只雄性大鼠分为四组：对照组，服用 1%吐温 80；LZP 组，服用 2 毫克/千克/天；白藜芦醇组，服用 50 毫克/千克/天；LZP 加白藜芦醇组，服用相同剂量的 LZP 和白藜芦醇。每天口服治疗，持续 6 周。动物在开阔地和Y迷宫行为测试后被安乐死。对特定脑区的 GABA、谷氨酸、单胺（去甲肾上腺素、多巴胺和血清素）及其代谢物、DNA 断裂（8-羟基-2-脱氧鸟苷或 8-HdG）、脑源性神经营养因子（BDNF）和 Ca-ATP 酶进行了神经化学分析：白藜芦醇疗法改善了大脑皮层、海马和纹状体中的GABA、谷氨酸、单胺及其代谢产物。此外，白藜芦醇还能减少 DNA 断裂（8- HdG），并显著抵消 LZP 诱导的 Ca-ATP 酶下调（p < 0.05）。白藜芦醇还能逆转LZP诱导的Y迷宫和空场测试中的行为变化：结论：白藜芦醇具有类似苯二氮卓的抗焦虑作用，并对 LZP 诱导的不良反应具有神经保护能力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.